MRI Findings in Nonlesional Hypertrophic Olivary Degeneration

Chris N. Gu, Carrie Carr, Timothy J Kaufmann, Amy L. Kotsenas, Christopher H. Hunt, Christopher P. Wood

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

PURPOSE: Investigate the relative frequency of nonlesional versus lesional hypertrophic olivary degeneration (HOD) and potential explanations for nonlesional HOD. METHODS: Our radiology report database was queried for "HOD" in all head MRI reports between 7/1/2002 and 7/1/2013 and identified 138 patients. Specific absence of HOD or cases with lesions within the dento-rubro-olivary pathway (DROP) or extending into the inferior olivary nuclei (ION) were excluded (22 in total). For included patients, 19 locations with the anatomic potential to connect to the ION or DROP were reviewed and grouped into embryological categories, along with the use of the drug metronidazole. RESULTS: A total of 51 of 116 (44%) HOD patients did not have a causative lesion in the DROP. The 27/51 (53%) of these patients had progressive ataxia with palatal tremor (PAPT). The 28/51 (55%) patients had one or more lesions outside of the DROP and one of these 28 patients used metronidazole. The remaining 23/51 (45%; 19% of total HOD cohort) patients had no additional lesions in the brain and 6 of these 23 patients did not have a clinical diagnosis of PAPT. CONCLUSION: Forty-four percent of patients with HOD did not demonstrate an MRI-identifiable lesion in the DROP, and 45% of those patients did not have identifiable brain lesions outside of the DROP. Thus, nearly a fifth of HOD cases may be truly idiopathic. A majority of patients without a DROP lesion had bilateral HOD and two-thirds were male.

Original languageEnglish (US)
Pages (from-to)813-817
Number of pages5
JournalJournal of Neuroimaging
Volume25
Issue number5
DOIs
StatePublished - Sep 1 2015

Fingerprint

Olivary Nucleus
Metronidazole
Tremor
Ataxia
Brain
Radiology
Head
Databases
Pharmaceutical Preparations

Keywords

  • Dento-rubro-olivary pathway
  • Hypertrophic olivary degeneration

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology

Cite this

MRI Findings in Nonlesional Hypertrophic Olivary Degeneration. / Gu, Chris N.; Carr, Carrie; Kaufmann, Timothy J; Kotsenas, Amy L.; Hunt, Christopher H.; Wood, Christopher P.

In: Journal of Neuroimaging, Vol. 25, No. 5, 01.09.2015, p. 813-817.

Research output: Contribution to journalArticle

Gu, Chris N. ; Carr, Carrie ; Kaufmann, Timothy J ; Kotsenas, Amy L. ; Hunt, Christopher H. ; Wood, Christopher P. / MRI Findings in Nonlesional Hypertrophic Olivary Degeneration. In: Journal of Neuroimaging. 2015 ; Vol. 25, No. 5. pp. 813-817.
@article{5210a62b39c14573b9781cfe58a00eff,
title = "MRI Findings in Nonlesional Hypertrophic Olivary Degeneration",
abstract = "PURPOSE: Investigate the relative frequency of nonlesional versus lesional hypertrophic olivary degeneration (HOD) and potential explanations for nonlesional HOD. METHODS: Our radiology report database was queried for {"}HOD{"} in all head MRI reports between 7/1/2002 and 7/1/2013 and identified 138 patients. Specific absence of HOD or cases with lesions within the dento-rubro-olivary pathway (DROP) or extending into the inferior olivary nuclei (ION) were excluded (22 in total). For included patients, 19 locations with the anatomic potential to connect to the ION or DROP were reviewed and grouped into embryological categories, along with the use of the drug metronidazole. RESULTS: A total of 51 of 116 (44{\%}) HOD patients did not have a causative lesion in the DROP. The 27/51 (53{\%}) of these patients had progressive ataxia with palatal tremor (PAPT). The 28/51 (55{\%}) patients had one or more lesions outside of the DROP and one of these 28 patients used metronidazole. The remaining 23/51 (45{\%}; 19{\%} of total HOD cohort) patients had no additional lesions in the brain and 6 of these 23 patients did not have a clinical diagnosis of PAPT. CONCLUSION: Forty-four percent of patients with HOD did not demonstrate an MRI-identifiable lesion in the DROP, and 45{\%} of those patients did not have identifiable brain lesions outside of the DROP. Thus, nearly a fifth of HOD cases may be truly idiopathic. A majority of patients without a DROP lesion had bilateral HOD and two-thirds were male.",
keywords = "Dento-rubro-olivary pathway, Hypertrophic olivary degeneration",
author = "Gu, {Chris N.} and Carrie Carr and Kaufmann, {Timothy J} and Kotsenas, {Amy L.} and Hunt, {Christopher H.} and Wood, {Christopher P.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/jon.12267",
language = "English (US)",
volume = "25",
pages = "813--817",
journal = "Journal of Neuroimaging",
issn = "1051-2284",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - MRI Findings in Nonlesional Hypertrophic Olivary Degeneration

AU - Gu, Chris N.

AU - Carr, Carrie

AU - Kaufmann, Timothy J

AU - Kotsenas, Amy L.

AU - Hunt, Christopher H.

AU - Wood, Christopher P.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - PURPOSE: Investigate the relative frequency of nonlesional versus lesional hypertrophic olivary degeneration (HOD) and potential explanations for nonlesional HOD. METHODS: Our radiology report database was queried for "HOD" in all head MRI reports between 7/1/2002 and 7/1/2013 and identified 138 patients. Specific absence of HOD or cases with lesions within the dento-rubro-olivary pathway (DROP) or extending into the inferior olivary nuclei (ION) were excluded (22 in total). For included patients, 19 locations with the anatomic potential to connect to the ION or DROP were reviewed and grouped into embryological categories, along with the use of the drug metronidazole. RESULTS: A total of 51 of 116 (44%) HOD patients did not have a causative lesion in the DROP. The 27/51 (53%) of these patients had progressive ataxia with palatal tremor (PAPT). The 28/51 (55%) patients had one or more lesions outside of the DROP and one of these 28 patients used metronidazole. The remaining 23/51 (45%; 19% of total HOD cohort) patients had no additional lesions in the brain and 6 of these 23 patients did not have a clinical diagnosis of PAPT. CONCLUSION: Forty-four percent of patients with HOD did not demonstrate an MRI-identifiable lesion in the DROP, and 45% of those patients did not have identifiable brain lesions outside of the DROP. Thus, nearly a fifth of HOD cases may be truly idiopathic. A majority of patients without a DROP lesion had bilateral HOD and two-thirds were male.

AB - PURPOSE: Investigate the relative frequency of nonlesional versus lesional hypertrophic olivary degeneration (HOD) and potential explanations for nonlesional HOD. METHODS: Our radiology report database was queried for "HOD" in all head MRI reports between 7/1/2002 and 7/1/2013 and identified 138 patients. Specific absence of HOD or cases with lesions within the dento-rubro-olivary pathway (DROP) or extending into the inferior olivary nuclei (ION) were excluded (22 in total). For included patients, 19 locations with the anatomic potential to connect to the ION or DROP were reviewed and grouped into embryological categories, along with the use of the drug metronidazole. RESULTS: A total of 51 of 116 (44%) HOD patients did not have a causative lesion in the DROP. The 27/51 (53%) of these patients had progressive ataxia with palatal tremor (PAPT). The 28/51 (55%) patients had one or more lesions outside of the DROP and one of these 28 patients used metronidazole. The remaining 23/51 (45%; 19% of total HOD cohort) patients had no additional lesions in the brain and 6 of these 23 patients did not have a clinical diagnosis of PAPT. CONCLUSION: Forty-four percent of patients with HOD did not demonstrate an MRI-identifiable lesion in the DROP, and 45% of those patients did not have identifiable brain lesions outside of the DROP. Thus, nearly a fifth of HOD cases may be truly idiopathic. A majority of patients without a DROP lesion had bilateral HOD and two-thirds were male.

KW - Dento-rubro-olivary pathway

KW - Hypertrophic olivary degeneration

UR - http://www.scopus.com/inward/record.url?scp=84939227307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939227307&partnerID=8YFLogxK

U2 - 10.1111/jon.12267

DO - 10.1111/jon.12267

M3 - Article

C2 - 26073621

AN - SCOPUS:84939227307

VL - 25

SP - 813

EP - 817

JO - Journal of Neuroimaging

JF - Journal of Neuroimaging

SN - 1051-2284

IS - 5

ER -